The The Effect of Heparin Therapy on Platelet Number and Clotting Time
The platelet count and clotting time are typically examined in a test to determine platelet vulnerability. A normal platelet count often affects how quickly blood clots. A low platelet count will cause a prolonged clotting time, with the exception of some conditions such kidney failure, pulmonary embolism, acute CHD, haemophilia, and chronic liver disease. A normal clotting time value will be produced by a healthy platelet count. One anticoagulant drug that can be used to treat bleeding issues is heparin. In this study, patients who received heparin therapy and those who did not are contrasted in terms of platelet counts and bleeding times. This study employed an experiment to assess the platelet count and clotting time between heparin-treated individuals and patients receiving non-heparin medication. samples gathered by the process. According to the studies, patients on heparin had an average blood clotting time of 14.98 minutes as opposed to individuals not taking heparin therapy, who had an average blood clotting time of 7.43 minutes. Patients who did not receive heparin therapy had a mean platelet count of 165,250 cells/mm3, whereas those who did had a mean platelet count of 160,050 cells/mm3. The results of the study showed that there was no significant change in platelet count between patients getting heparin therapy and those receiving non-heparin therapy (sig 2-tailed: 0.311). Despite the significant variation in the value of clotting time between individuals taking heparin medication and those not (sig 2-tailed: 0.000). In this study, anticoagulants were found to have an impact on platelet quality but no impact on platelet quantity. The bleeding time examination variable should be included in future research, along with other variables, as a normal platelet count does not always translate into the same clotting time.
Baluwala, I., Favaloro, E. J., & Pasalic, L. (2017). Therapeutic monitoring of unfractionated heparin–trials and tribulations. Expert Review of Hematology, 10(7), 595-605.
Becker, R.C., Sexton, T.,& Smyth, S.S. (2021). Translational implications of platelets as vascular first responders. Circ Res. 2018;122(3), 506-522. https://doi.org/10.1161/CIRCRESAHA.117.310939
Boonyawat, K., O’Brien, S. H., & Bates, M.S. (2017). How I treat heavy menstrual bleeding associated with anticoagulants. Blood, The Journal of the American Society of Hematology, 130(24), 2603–2609. https://doi.org/10.1182/blood-2017-07-797423
Capodanno, D., & Angiolillo, D. A. (2012). Antithrombotic Therapy in Patients With Chronic Kidney Disease. Circulation, 125(21), 2649–2661. https://doi.org/10.1161/CIRCULATIONAHA.111.084996
Charness, G., Gneezy, U., & Kuhn, M. A., (2012). Experimental methods: Between-subject and within-subject design. Journal of economic behavior & organization, 81(1), 1-8. ISSN 0167-2681. https://doi.org/10.1016/j.jebo.2011.08.009
Greene, L.A., Chen, S., Seery, C., Imahiyerobo, A.M. & Bussel, J.B. (2014), Beyond the platelet count: immature platelet fraction and thromboelastometry correlate with bleeding in patients with immune thrombocytopenia. Br J Haematol, 166, 592-600. https://doi.org/10.1111/bjh.12929
Harsono. (2012). Pengaruh Aktifitas Fisik terhadap beda rerata waktu pembekuan dalam system koagulasi. http//www.researchgate.net
Kalathottukaren, M. T., Abraham, L., Kapopara, P.A., Lai, B. F. L., Shenoi, R. A., Rosell, F. I., Conway, E. M., Pryzdial, E. L. G., Morrissey, J. H., Haynes, C.A., & Kizhakkedathu, J. N. (2016). Alteration of blood clotting and lung damage by protamine are avoided using the heparin and polyphosphate inhibitor UHRA. Blood, 129(10), 1368–1379. https://doi.org/10.1182/blood-2016-10-747915
Kim, T. K. (2015). T test as a parametric statistic. Korean journal of anesthesiology, 68(6): 540-546. DOI:https://doi.org/10.4097/kjae.2015.68.6.540
Kowata, S., Isogai, S., Murai, K. Ito S., Tohyama, K., Ema, M., Hitomi, J., & Ishida, Y. (2014). Platelet demand modulates the type of intravascular protrusion of megakaryocytes in bone marrow. Thrombosis and haemostasis,112(04), 743-756. DOI: https://doi.org/10.1160/TH14-02-0123
Loredana, B., Emanuela, F., & Paolo G. (2021). Learning the Ropes of Platelet Count Regulation: Inherited Thrombocytopenias. Journal of Clinical Medicine, 10(3), 533: 2077-0383. Doi: https://doi.org/10.3390/jcm10030533. https://www.mdpi.com/2077-0383/10/3/533
Nguyen, T. H., Greinacher, A., & Mihaela, D. (2015). Quantitative description of thermodynamic and kinetic properties of the platelet factor 4/heparin bonds. Nanoscale, 7(22), 10130-10139. http://dx.doi.org/10.1039/C5NR02132D
Pécourt, M. (2021). Highlights on HELLP syndrome. JMV-Journal de Médecine Vasculaire. 46(5–6), 207-208. ISSN 2542-4513. https://doi.org/10.1016/j.jdmv.2021.09.001
Periayah, M. H., Halim, A. S., & Saad, A. Z. M. (2017). Mechanism action of platelets and crucial blood coagulation pathways in hemostasis. International journal of hematology-oncology and stem cell research, 11(4), 319. PMID: 29340130; PMCID: PMC5767294.
Roveny. (2016). Trombositopenia Akibat Heparin, IAI journal, 43(9), 659-664.
Sugiyono. (2016). Metode Penelitian kuantitatif, kualitatif dan R&D. Alfabeta.
Wijaya, Wimardy Leonard., & Arifin, Johan. (2013). Pengaruh Pemberian Heparin Subkutan Sebagai Profilaksis Trombosis Vena Dalam (TVD) Terhadap Jumlah Trombosit Pada Pasien Sakit Kritis Di ICU RSUP Dr Kariadi. Jurnal Kedokteran Diponegoro, 2(1).
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.